Dr Sumanth Gandra, Resident Scholar and Fellow, Center for Disease Dynamics,
Economics & Policy (CDDEP)
pediatric fixed dose
combinations for
treatment of TB and
new drugs for HIV.
Inappropriate and
overuse of antibiotics
is one of the major
drivers of antibiotic
resistance. The
comprehensive review
of anti-bacterial agents
in this updated list,
guides member states
to take steps to reduce
the inappropriate
use of antibiotics.
Addition of new
pediatric friendly
formulations and a
new drug (delamanid)
for treatment of TB
is very important
in the control and
management of TB,
especially for children.
Any specific
reasons for doing
that after two years
and not on annual
basis?
I assume the reason
for updating every two
years instead of yearly,
BIOVOICENEWS.COM
39